BioStem Technologies Company Description
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States.
It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use.
The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014.
BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
| Country | United States |
| Founded | 2006 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Jason Matuszewski |
Contact Details
Address: 4901 Northwest 17th Way Fort Lauderdale, Florida 33309 United States | |
| Phone | 954 380 8342 |
| Website | biostemtechnologies.com |
Stock Details
| Ticker Symbol | BSEM |
| Exchange | OTCMKTS |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US0906842002 |
| SIC Code | 8731 |
Key Executives
| Name | Position |
|---|---|
| Jason V. Matuszewski | Chief Executive Officer, President, Secretary and Chairman |
| Brandon Poe | Chief Financial Officer and Independent Director |
| Andrew Van Vurst CTBS | Chief Operating Officer and Director |
| Michael A. Fortunato CPA | Chief Accounting Officer |
| Noah Agron | Vice President of Corporate Finance and Strategy |